NEW YORK (GenomeWeb News) – ImaGenes will provide its next-generation sequencing customers with a license to CLC Bio’s Genomics Workbench for sequence analysis applications under a new bundling agreement, CLC Bio said today.

ImaGenes Director of Bioinformatics and Services Steffen Henning said in a statement that the firm sought "a software platform which we could use to present our research results to our customers in an easy, coherent, and user-friendly way," and which would function with various next-generation sequencing platforms.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.